Palisade Bio (PALI) 주식 개요

는 임상 단계의 바이오 제약 회사로, 미국에서 말단 회장과 결장에 표적 전달되도록 설계된 경구용 포스포디에스테라제-4 억제제 원약을 개발하는 데 주력하고 있습니다. 자세히 보기

PALI 펀더멘털 분석
스노우플레이크 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 건전성	6/6
배당	0/6

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 USD$1m 미만입니다($0)

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 3개월 동안 주가 변동성이 US 시장과 비교해 높았습니다.

PALI Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Palisade Bio, Inc. 경쟁사

가격 이력 및 성과

Palisade Bio 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가	US$1.95
52주 최고가	US$2.86
52주 최저가	US$0.53
베타	1.53
1개월 변동	-6.25%
3개월 변동	8.94%
1년 변동	141.64%
3년 변동	-90.37%
5년 변동	-99.90%
IPO 이후 변동	-99.90%

최근 뉴스 및 업데이트

분석 기사 • May 22

We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Palisade Bio ( NASDAQ:PALI...

Recent updates

분석 기사 • May 22

We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Palisade Bio ( NASDAQ:PALI...

Seeking Alpha • Dec 23

Palisade Bio: Gut Prodrug For IBD With Catalysts

Summary Palisade Bio’s bull thesis centers on PALI-2108. This is a gut-targeted PDE4 prodrug aiming for local efficacy with fewer systemic PDE4 side effects. The main target indications are UC and FSCD, which promise a sizable TAM if PALI-2108 ultimately succeeds. Naturally, this means PALI’s story remains early-stage and highly data-dependent. Yet, they have a compelling near-term catalyst stack. PALI’s recent October 2025 raise also materially improved their cash runway and liquidity. Using those numbers, its valuation looks compelling relative to its peers. Thus, I lean towards a speculative "Buy" rating on PALI. Read the full article on Seeking Alpha

Seeking Alpha • Oct 11

Palisade Bio announces CEO transition

Palisade Bio (NASDAQ:PALI) announced an executive leadership transition effective October 10, 2022, Thomas Hallam, Ph.D., ceased his duties as CEO. The company’s board of directors has appointed JD Finley, current CFO, as interim CEO, and Mr. Finley has assumed the duties of Dr. Hallam effective October 10, 2022. Prior to joining Palisade Bio, Mr. Finley was the CEO, president and CFO for PointAcross, a software company providing business messaging and communications services.

Seeking Alpha • Sep 15

Palisade Bio streamlines operations, including cutting 20% of employees

Palisade Bio (NASDAQ:PALI) is undergoing a program to streamline operations that includes focusing on lead clinical program LB1148 and laying off 20% of its staff. The gastrointestinal-focused biotech said it is implementing cost-savings measures of more than $1.5M per year. LB1148, a broad-spectrum serine protease inhibitor, is in phase 3 for GI surgery and phase 2 for cardiovascular surgery, both in terms of accelerating return of postoperative GI function. It is also in phase 2 in GI surgery for prevention of post-surgical abdominal adhesions. Seeking Alpha's Quant Rating views Palisade Bio (PALI) as a hold with high marks for valuation, profitability, and revisions.

Seeking Alpha • Aug 15

Palisade Bio GAAP EPS of -$0.12

Palisade Bio press release (NASDAQ:PALI): Q2 GAAP EPS of -$0.12. As of June 30, 2022, the company had cash and cash equivalents of $5M

Seeking Alpha • Jul 27

Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function

Palisade Bio (NASDAQ:PALI) said on Wednesday the first patient had been screened in a Phase 3 study testing its drug, LB1148, to help return bowel function in adult patients undergoing gastrointestinal surgery. The company said it was working to enroll patients and expects to complete enrollment within the next 18-24 months. The drug LB1148 is being developed for administration before the surgeries. The trial is set to enroll about 600 patients and will assess the safety and efficacy of LB1148. The primary endpoint is time to recovery of the upper and lower gastrointestinal tract following surgery. (PALI) rose 1.3% before the bell.

Seeking Alpha • Jun 29

Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy

Palisade Bio (NASDAQ:PALI) is trading 10% higher after it begun Phase 3 study evaluating its drug, LB1148, to help return bowel function in patients undergoing gastrointestinal surgery. The late-stage study will enroll about 600 patients. The primary endpoint of the study is time to recovery of the upper and lower gastrointestinal tract following surgery, which is defined as the time from the end of surgery to the toleration of food and first bowel movement.

분석 기사 • Mar 28

Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

주주 수익률

	PALI	US Biotechs	US 시장
7D	7.7%	3.1%	1.2%
1Y	141.6%	34.6%	28.7%

수익률 대 산업: PALI은 지난 1년 동안 34.6%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: PALI은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is PALI's price volatile compared to industry and market?
PALI volatility
PALI Average Weekly Movement	12.4%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

안정적인 주가: PALI의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.

시간에 따른 변동성: PALI의 주간 변동성은 지난 1년간 18%에서 12%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.

회사 소개

설립	직원 수	CEO	웹사이트
2001	14	J. Finley	www.palisadebio.com

임상 단계의 바이오 제약 회사인 팰리세이드 바이오는 미국에서 회장과 결장에 표적 전달되도록 설계된 경구용 포스포디에스테라제-4 억제제 시약을 개발하는 회사입니다. 주요 임상 제품 후보로는 궤양성 대장염 및 섬유협착성 크론병을 포함한 염증성 장 질환 환자를 치료하기 위한 임상 1b상 시험 중인 PALI-2108이 있습니다. 회사는 화합물의 개발, 제조 및 상용화를 위해 자이언트 파마(Giiant Pharma, Inc.)와 연구 협력 및 라이선스 계약을 체결했으며, 뉴소아라 공동 개발을 유지하기 위한 목적으로 캘리포니아 대학교 리전트와 라이선스 계약을, 뉴소아라 바이오파마와 공동 개발 및 유통 계약을 체결했습니다.

Palisade Bio, Inc. 기초 지표 요약

Palisade Bio의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
PALI 기초 통계
시가총액	US$326.48m
순이익 (TTM)	-US$24.15m
매출 (TTM)	n/a

0.0x

주가매출비율(P/S)

-13.5x

주가수익비율(P/E)

PALI는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
PALI 손익계산서 (TTM)
매출	US$0
매출원가	US$0
총이익	US$0
기타 비용	US$24.15m
순이익	-US$24.15m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

해당 없음

주당순이익(EPS)	-0.14
총이익률	0.00%
순이익률	0.00%
부채/자본 비율	0%

PALI의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/25 06:37
종가	2026/05/22 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Palisade Bio, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
William Wood	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets
Mitchell Kapoor	H.C. Wainwright & Co.

Palisade Bio (PALI) 주식 개요

위험 분석

Palisade Bio, Inc. 경쟁사

Benitec Biopharma

SAB Biotherapeutics

Inhibikase Therapeutics

Lyell Immunopharma

가격 이력 및 성과

최근 뉴스 및 업데이트

We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn

Palisade Bio Inc Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure And Sustained IC90 Coverage Supporting Once-Daily Dosing In Ulcerative Colitis

Palisade Bio, Inc., Annual General Meeting, Jun 10, 2026

Price target increased by 7.7% to US$11.13

Palisade Bio, Inc. Reports Positive Topline Data From Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease

Palisade Bio, Inc. Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 At ECCO 2026

Recent updates

We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn

Palisade Bio Inc Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure And Sustained IC90 Coverage Supporting Once-Daily Dosing In Ulcerative Colitis

Palisade Bio, Inc., Annual General Meeting, Jun 10, 2026

Price target increased by 7.7% to US$11.13

Palisade Bio, Inc. Reports Positive Topline Data From Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease

Palisade Bio, Inc. Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 At ECCO 2026

Palisade Bio, Inc. Appoints Bram Verstockt to Clinical Advisory Board

Palisade Bio, Inc. Announces Clinical Advisory Board Changes

Palisade Bio, Inc. announced that it expects to receive $0.5 million in funding from Crohn's & Colitis Foundation, Inc.

Palisade Bio, Inc. Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

Palisade Bio: Gut Prodrug For IBD With Catalysts

Price target increased by 29% to US$10.33

Palisade Bio, Inc. Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Palisade Bio Announces First Patients Dosed in Phase 1B Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $120 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Palisade Bio, Inc., Annual General Meeting, Oct 17, 2025

Palisade Bio, Inc. Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

New major risk - Financial position

Palisade Bio, Inc. Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, Pali-2108

High number of new and inexperienced directors

New minor risk - Share price stability

Palisade Bio, Inc. Appoints Emil Chuang to Its Board of Directors

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering.

Palisade Bio, Inc. Reports Positive Phase 1A Results for PALI-2108

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio, Inc. Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as A Promising Colon-Specific Pde4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Palisade Bio Receives Notice from the Nasdaq Stock Market

Palisade Bio, Inc. Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

New major risk - Financial position

Palisade Bio, Inc. Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1A/B Study of PALI-2108

Palisade Bio, Inc. Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

High number of new and inexperienced directors

Palisade Bio, Inc. Appoints Brian G. Feagan to its Clinical Advisory Board

Palisade Bio, Inc. Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-To-Severe Ulcerative Colitis Is to Be Safe and Well Tolerated in Treated Subjects

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis

Price target increased by 33% to US$45.00

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

New major risk - Financial position

Palisade Bio, Inc. Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio, Inc. Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Leading Product Candidate, PALI-2108

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024

Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108

Price target decreased by 33% to US$22.50

Palisade Bio, Inc. announced that it has received $3.999943 million in funding

Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors

Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements

Palisade Bio, Inc. Announces Advisory Board Appointments

New major risk - Share price stability

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

New major risk - Revenue and earnings growth

Price target decreased by 81% to US$3.00

Palisade Bio Receives Non-Compliance Notice from Nasdaq